LOW GRADE SEROUS OVARIAN CANCER
Clinical trials for LOW GRADE SEROUS OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new LOW GRADE SEROUS OVARIAN CANCER trials appear
Sign up with your email to follow new studies for LOW GRADE SEROUS OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug cocktail targets Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a combination of three drugs (avutometinib, defactinib, and letrozole) in 20 women with low-grade serous ovarian cancer who cannot have surgery right away. The goal is to see if the drugs can shrink tumors or control the cancer. Researchers will also monitor side…
Matched conditions: LOW GRADE SEROUS OVARIAN CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC
-
New drug duo aims to shrink returning ovarian tumors
Disease control Recruiting nowThis study tests an experimental drug called ubamatamab, alone or with another drug (cemiplimab), in people whose ovarian or uterine cancer has come back. The main goals are to check safety, find the best dose, and see if the treatment can shrink tumors. About 890 participants wi…
Matched conditions: LOW GRADE SEROUS OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 08, 2026 13:05 UTC
-
New hope for rare ovarian cancer: drug combo enters final testing phase
Disease control Recruiting nowThis phase 3 study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer has returned after platinum-based therapy will be randoml…
Matched conditions: LOW GRADE SEROUS OVARIAN CANCER
Phase: PHASE3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated May 26, 2026 08:20 UTC